Argus Has Lowered Expectations for Becton, Dickinson and Company (NYSE:BDX) Stock Price

Becton, Dickinson and Company (NYSE:BDX) had its target price reduced by analysts at Argus from $230.00 to $180.00 in a report issued on Monday,Benzinga reports. The firm presently has a “buy” rating on the medical instruments supplier’s stock. Argus’ price target indicates a potential upside of 15.47% from the company’s current price.

Other analysts also recently issued reports about the stock. Barclays began coverage on shares of Becton, Dickinson and Company in a research report on Tuesday, February 10th. They issued an “overweight” rating and a $202.00 price objective on the stock. Jefferies Financial Group dropped their price target on shares of Becton, Dickinson and Company from $220.00 to $190.00 and set a “buy” rating on the stock in a research note on Tuesday, February 10th. Bank of America lifted their price target on Becton, Dickinson and Company from $190.00 to $207.00 and gave the company a “neutral” rating in a report on Monday, January 5th. Piper Sandler reiterated a “neutral” rating and set a $170.00 price objective (down from $205.00) on shares of Becton, Dickinson and Company in a research report on Tuesday, February 10th. Finally, Citigroup decreased their price objective on Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating for the company in a report on Tuesday, February 10th. Six equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $191.62.

Becton, Dickinson and Company Price Performance

Shares of BDX opened at $155.89 on Monday. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $187.35. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.05 and a quick ratio of 0.58. The stock has a fifty day moving average price of $183.69 and a 200 day moving average price of $188.31. The company has a market cap of $44.39 billion, a P/E ratio of 25.43, a PEG ratio of 11.33 and a beta of 0.24.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.81 by $0.10. The company had revenue of $5.25 billion for the quarter, compared to analysts’ expectations of $5.15 billion. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The firm’s quarterly revenue was up 1.6% compared to the same quarter last year. During the same period last year, the business posted $3.43 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. On average, research analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company declared that its board has initiated a stock buyback plan on Tuesday, January 27th that authorizes the company to repurchase $10.00 million in outstanding shares. This repurchase authorization authorizes the medical instruments supplier to reacquire up to 0% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s board believes its shares are undervalued.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,610 shares of Becton, Dickinson and Company stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $207.46, for a total value of $334,010.60. Following the transaction, the executive vice president directly owned 12,095 shares in the company, valued at $2,509,228.70. The trade was a 11.75% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Bertram L. Scott sold 953 shares of the company’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total value of $174,027.33. Following the sale, the director directly owned 36,763 shares of the company’s stock, valued at approximately $6,713,291.43. This represents a 2.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 2,787 shares of company stock valued at $551,391. Corporate insiders own 0.40% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in BDX. Brighton Jones LLC boosted its holdings in shares of Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after purchasing an additional 877 shares during the period. Oppenheimer Asset Management Inc. increased its stake in Becton, Dickinson and Company by 71.4% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 82,655 shares of the medical instruments supplier’s stock valued at $15,471,000 after buying an additional 34,437 shares during the period. Transcend Capital Advisors LLC increased its stake in Becton, Dickinson and Company by 88.2% in the 3rd quarter. Transcend Capital Advisors LLC now owns 5,794 shares of the medical instruments supplier’s stock valued at $1,084,000 after buying an additional 2,715 shares during the period. Belpointe Asset Management LLC purchased a new stake in Becton, Dickinson and Company in the 3rd quarter worth approximately $650,000. Finally, Vanguard Group Inc. boosted its stake in shares of Becton, Dickinson and Company by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 32,455,790 shares of the medical instruments supplier’s stock valued at $6,074,750,000 after buying an additional 147,041 shares during the period. 86.97% of the stock is owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.